Cargando…

CA125 and Ovarian Cancer: A Comprehensive Review

SIMPLE SUMMARY: CA125 has been the most promising biomarker for screening ovarian cancer; however, it still does not have an acceptable accuracy in population-based screening for ovarian cancer. In this review article, we have discussed the role of CA125 in diagnosis, evaluating response to treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charkhchi, Parsa, Cybulski, Cezary, Gronwald, Jacek, Wong, Fabian Oliver, Narod, Steven A., Akbari, Mohammad R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763876/ https://www.ncbi.nlm.nih.gov/pubmed/33322519 http://dx.doi.org/10.3390/cancers12123730

Ejemplares similares

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Potential clinical utility of liquid biopsies in ovarian cancer
por: Zhu, Jie Wei, et al.
Publicado: (2022)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland
por: Jasiewicz, Andrzej, et al.
Publicado: (2022)

Genetic susceptibility to hereditary non-medullary thyroid cancer
por: Kamani, Tina, et al.
Publicado: (2022)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

What Is Known about Breast Cancer in Young Women?
por: Zhu, Jie Wei, et al.
Publicado: (2023)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

The Clinical Outcome of Laparoscopic Surgery for Endometriosis on Pain, Ovarian Reserve, and Cancer Antigen 125 (CA-125): A Cohort Study
por: Sarbazi, Fereshte, et al.
Publicado: (2021)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

RECQL: a DNA helicase in breast cancer
por: Akbari, Mohammad R., et al.
Publicado: (2015)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

Serum Essential Elements and Survival after Cancer Diagnosis
por: Lubiński, Jan, et al.
Publicado: (2023)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

An appraisal of genetic testing for prostate cancer susceptibility
por: Finch, Amy, et al.
Publicado: (2022)

Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
por: Gupta, Digant, et al.
Publicado: (2009)

Emerging applications of tumour-educated platelets in the detection and prognostication of ovarian cancer
por: Zhu, Jiewei, et al.
Publicado: (2023)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families
por: Dębniak, Tadeusz, et al.
Publicado: (2015)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland
por: Baszuk, Piotr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qeklks7jga4pfqe77qi3loo81f